Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Mississippi for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Mississippi only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Mississippi (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Sharon Hong (NPI 1275820722)

Field	Value
Entity Type	Individual
Organization	Sharon Hong
Address	2550 Flowood Dr
City	Flowood
State	MS
ZIP	39232
Taxonomy	Rheumatology Physician
NPI Enumerated	July 6, 2011

Payer Source	Total Paid
Medicare	$2.1M
Medicaid	$0

Key Findings

Practice is concentrated on biologic and infused therapies consistent with a rheumatology service line: the top revenue drivers are drug-injection/infusion codes J0129, J1602, and J3262 (abatacept, golimumab, tocilizumab respectively), and the top 3 Medicare codes by revenue account for 57.5% of this provider's total Medicare revenue. These three biologic agents appear to form the core of the billable service mix rather than high-volume, complex E/M visits alone, indicating a clinic model built around drug administration and management of chronic inflammatory disease.

Revenue concentration is high: J0129 alone accounts for $575.9K (26.9% of Medicare revenue), with J1602 at $379K (17.7%) and J3262 at $275.4K (12.9%). With the precomputed top-3 share of 57.5% of Medicare revenue, a majority of the $2.1M Medicare lifetime revenue is driven by a small set of injectable biologics, which concentrates reimbursement exposure to these codes and associated drugs.

Infusion and chemotherapy-administration services are a meaningful component of the practice: 96413 (chemotherapy infusion) generated $62.5K (2.9% of Medicare revenue) and ranks #239 of 7514 providers nationally (97th percentile; notably above typical national volume for this code), while 96401 and 96415 also appear above typical national volumes. These high-percentile chemotherapy/infusion administration codes indicate the provider operates regular infusion sessions and bills for drug administration time in addition to the drug J-codes.

Office visit E/M volume for established patients is an outlier relative to national peers: 99213 produced $77.8K (3.6% of Medicare revenue) with 1.3K claims and ranks #3144 of 457151 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code). This suggests a heavier-than-average caseload of repeat, short outpatient visits in Medicare, which may reflect frequent follow-up visits tied to biologic treatment monitoring and dose management.

Competitive standing on biologics is modest-to-strong but not dominant nationally: J0129 ranks #177 of 1221 (85th percentile; typical, unremarkable volume), J1602 ranks #97 of 1041 (91th percentile; typical, unremarkable volume), and J3262 ranks #203 of 618 (67th percentile; typical, unremarkable volume). Additional biologic/injection codes such as J0897 ($218.2K; 10.2% and #821 of 10057, 92th percentile) and J1745 ($201.2K; 9.4% and #161 of 1352, 88th percentile) further show above-average placement in national rankings for multiple injectable agents, indicating a competitive regional presence in biologic administration.

This provider is effectively single-payer from a public program perspective: lifetime Medicare revenue is $2.1M while there is no Medicaid billing on file (none below — this provider has no Medicaid billing on file). The absence of Medicaid activity means the practice’s public-reimbursement exposure and growth opportunities are concentrated in Medicare beneficiaries rather than a mixed Medicare/Medicaid payer mix.

High-volume lab and phlebotomy activity supports in-office monitoring: 36415 (venipuncture) shows 1.7K claims, $13.3K revenue (0.6% of Medicare revenue) and ranks #1236 of 86467 providers nationally (99th percentile; typical, unremarkable volume for this code), while CBC 85025 shows 1.6K claims, $13K revenue (0.6%) and ranks #1305 of 32833 (96th percentile; typical, unremarkable volume). Multiple other lab panels (86140, 85652, 80076) also rank in the mid-90s percentiles, consistent with routine serial monitoring tied to immunomodulatory and biologic therapy.

Provider tenure is established: NPI was enumerated on 2011-07-06 (~15 years ago), indicating the clinician has been in the NPI registry long enough to build a stable Medicare billing profile dominated by biologic drug administration and related monitoring services. This longevity supports the interpretation that the current service mix is sustained rather than a short-term fluctuation.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

33 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	17,450	$30	$575.9K
J1602	Injection, golimumab, 1 mg, for intravenous use	37,900	$10	$379K
J3262	Injection, tocilizumab, 1 mg	55,080	$10	$275.4K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	61,600	$1	$246.4K
J0897	Injection, denosumab, 1 mg	12,120	$20	$218.2K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	7,740	$30	$201.2K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,320	$60	$77.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	730	$90	$62.5K
96401	The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient.	560	$50	$26.4K
36415	In this procedure, the provider inserts a needle into a vein to collect a blood sample.	1,660	$10	$13.3K

Showing 1–10 of 33

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 33 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Mississippi Distribution

Sharon Hong — 9 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Mississippi

Full comparison — all codes billed, vs. state median

33 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	3	10	8,840	$30	$367.2K
J3262	4	10	55,080	$1	$299.4K
J1602	2	10	18,250	$10	$265.7K
J0717	3	10	36,000	$1	$144.1K
J0897	15	110	3,030	$20	$95.7K
J1745	2	20	2,470	$30	$87.5K
96413	6	70	100	$80	$22.6K
99213	55	4,000	100	$50	$10.3K
96401	2	60	80	$50	$7.1K
99204	416	2,150	40	$100	$5.8K

Showing 1–10 of 33

Related Providers

Other providers that share a Tax Identification Number (TIN) with Sharon Hong, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Jordan Smith	MS	Family Nurse Practitioner	$1.1M	$0
Teresa Crout	MS	Rheumatology Physician	$1.1M	$0

Nearby Providers

Other providers in the same ZIP code as Sharon Hong, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Rem East LLC	MS	Community/Behavioral Health Agency	$0	$97M
Love And Faith Personal Care And Respite Services	MS	Home Health Agency	$0	$24.3M
M-d Medical Services, Inc.	MS	Parenteral & Enteral Nutrition Supplies (DME)	$0	$18M
River Oaks Hospital LLC	MS	General Acute Care Hospital	$0	$16.6M
National Seating & Mobility, Inc.	MS	Durable Medical Equipment & Medical Supplies	$0	$12.5M
Madison Physician Surgery Center, LLC	MS	Ambulatory Surgical Clinic/Center	$12.3M	$30.3K
Mobility Medical Inc	MS	Oxygen Equipment & Supplies (DME)	$0	$10.4M
Prescribed Pediatric Extended Care, Inc	MS	Medically Fragile Infants and Children Day Care	$0	$9.5M
Women's Health Associates, PLLC	MS	Obstetrics & Gynecology Physician	$0	$9.4M
Rem East LLC	MS	Developmentally Disabled Services Day Training Agency	$0	$7.8M

Sharon Hong — Billing Profile & Reimbursement Data

Sign up for Sharon Hong — Billing Profile & Reimbursement Data policy alerts

Sharon Hong — Billing Profile & Reimbursement Data

Sign up for Sharon Hong — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References